数字化演进:诺和诺德向基于本体的数据管理的转型
Digital Evolution: Novo Nordisk's Shift to Ontology-Based Data Management
AI总结:
本文介绍诺和诺德研究与早期开发部门采用 OBDM 战略实施数字化转型的技术蓝图与组织变革方法,并总结其对 AI 驱动数据联邦、发现及数据驱动药物发现的经验。
摘要:
生物医学数据正呈指数级增长,对其进行管理也日益具有挑战性。尽管可发现、可访问、可互操作、可重用(FAIR)数据原则提供了指导,但事实证明,要采纳这些原则十分困难,尤其是在制药公司等大型企业中。在本手稿中,我们描述了如何在诺和诺德研究与早期开发部门利用基于本体的数据管理(OBDM)战略推进数字化转型。其中,我们既纳入了技术蓝图,也纳入了组织变革管理方法。我们进一步讨论了这样的 OBDM 生态系统如何在组织由人工智能推动的数据联邦与数据发现的数字化愿景中发挥关键作用。本文旨在分享经验教训,以促进与正应对类似挑战的各方开展对话,同时共同推动数据管理、语义学和数据驱动药物发现领域的工作。
英文摘要:
Biomedical data is growing exponentially, and managing it is increasingly challenging. While Findable, Accessible, Interoperable and Reusable (FAIR) data principles provide guidance, their adoption has proven difficult, especially in larger enterprises like pharmaceutical companies. In this manuscript, we describe how we leverage an Ontology-Based Data Management (OBDM) strategy for digital transformation in Novo Nordisk Research & Early Development. Here, we include both our technical blueprint and our approach for organizational change management. We further discuss how such an OBDM ecosystem plays a pivotal role in the organizations digital aspirations for data federation and discovery fuelled by artificial intelligence. Our aim for this paper is to share the lessons learned in order to foster dialogue with parties navigating similar waters while collectively advancing the efforts in the fields of data management, semantics and data driven drug discovery.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。